Recent Updates
Recently added Catalysts
RCEL Positive Sentiment Score: 70/100

AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference

Key Takeaway: AVITA Medical, a regenerative medicine company, announced that its CFO, David O'Toole, will present at the TD Cowen 44th Annual Health Care Conference. The presentation is scheduled for March 5, 2024. The company's RECELL System is at the forefront of its product offerings, approved for various treatment applications including thermal burns and vitiligo. The event will include a live audio webcast available on their website, along with a replay for 90 days post-event.

Market Sentiment Analysis

POSITIVE FACTORS

  • AVITA Medical is presenting at a significant healthcare conference, indicating confidence in their growth and engagement with the market.
  • The company's innovative RECELL System shows potential for improving treatment outcomes in wound care and skin restoration.

Full Press Release Details

VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that David O’Toole, Chief Financial Officer, will present at TD Cowen’s 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 9:50 a.m. Eastern Time.
A live audio webcast of the presentation will be available under the Events & Presentations section of AVITA Medical's website at https://ir.avitamedical.com. A replay of the webcast will be available at the same location for approximately 90 days following the conclusion of the event.
About AVITA Medical, Inc.
AVITA Medical® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL® System, approved by the Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, in the United States.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

Tags

avita medical webcast
avita medical presentation

Frequently Asked Questions

When is AVITA Medical's presentation at the TD Cowen Conference?

The presentation is scheduled for March 5, 2024, at 9:50 a.m. Eastern Time.

How can I access the live webcast of AVITA Medical's presentation?

The live audio webcast will be available on AVITA Medical's website under Events & Presentations.

What is the RECELL System used for?

The RECELL System is used for treating thermal burns, skin defects, and vitiligo lesions.

What is unique about AVITA Medical's RECELL technology?

RECELL uses a patient's own skin to create Spray-On Skin™ Cells, enhancing healing.

Which markets accept the RECELL System for skin healing?

The RECELL System is approved in the U.S., Australia, Europe, and Japan.

Last updated: Feb 29, 2024